

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

RYAN PHILLIPS UTRECHT & MACKINNON

2. Address:

1133 CONNECTICUT AVENUE, NW SUITE 300, WASHINGTON, DC 20036

3. Principal place of business (if different from line 2):

Country: City: State/Zip(or Country):

4. Contact Name: RODNEY C. HOPPE

Telephone: 202-293-1177

E-mail (optional): rodney@rpum.com

Senate ID #: 30187-636

House ID #: 30680039

7. Client Name: Self

PFIZER INC.

TYPE OF REPORT

8. Year 2006 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): 60,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): _____

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- Method A.** Reporting amounts using LDA definitions only
 Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
 Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: RYAN PHILLIPS UTRECHT & MACKINNON Client Name: PFIZER INC.

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

H.R. 563, Prescription Drug Affordability Act of 2005 H.R. 753/S. 184, Safe IMPORT Act of 2005, provisions dealing with pharmaceuticals H.R. 5/S. 1355, Help Efficient, Accessible, Low-cost, Timely Healthcare (HEALTH) Act of 2005 S. 455, Medicare Prescription Drug Price Reduction Act of 2005 H. 376, Medicare's Equitable Drugs for Seniors Act of 2005 H.R. 1626, Medicare Prescription Drug Improvement ActS. 239, Medicare Enhancements for Needed Drugs Act of 2005 H.R. 752/ S. 873, Medicare Prescription Drug Savings and Choice Act of 2005

17. House(s) of Congress and Federal agencies contacted:

US House
US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BERZOK, MATT

Covered Official Position (if applicable):

Name: HOPPE, RODNEY

Covered Official Position (if applicable):

Name: MACKINNON, JEFFREY M.

Covered Official Position (if applicable):

Name: NAPPI, DOUGLAS R.

Covered Official Position (if applicable):

Name: O'CONNOR, GEORGE C.

Covered Official Position (if applicable):

Name: PHILLIPS, WILLIAM D.

Covered Official Position (if applicable):

Name: PLANNING, MARK

Covered Official Position (if applicable):

Name: RYAN, THOMAS M.

Covered Official Position (if applicable):

Name: VASAPOLI, JOSEPH V.

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Registrant Name: RYAN PHILLIPS UTRECHT & MACKINNON Client Name: PFIZER INC.

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

Legislation on issues pertaining to proposed Medical Prescription drug benefits. Legislation on issues regarding FDA regulation of prescription drugs. Congressional oversight of drug safety. S. 109/H.R. 328 - Pharmaceutical Market Access Act of 2005. H.R. 700/S. 334 - Pharmaceutical Market Access & Drug Safety Act of 2005.

17. House(s) of Congress and Federal agencies contacted:

US House

US Senate

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BERZOK, MATT

Covered Official Position (if applicable):

Name: HOPPE, RODNEY

Covered Official Position (if applicable):

Name: MACKINNON, JEFFREY M.

Covered Official Position (if applicable):

Name: NAPPI, DOUGLAS R.

Covered Official Position (if applicable):

Name: O'CONNOR, GEORGE C.

Covered Official Position (if applicable):

Name: PHILLIPS, WILLIAM D.

Covered Official Position (if applicable):

Name: PLANNING, MARK

Covered Official Position (if applicable):

Name: RYAN, THOMAS M.

Covered Official Position (if applicable):

Name: VASAPOLI, JOSEPH V.

Covered Official Position (if applicable):

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

Signature: ON FILE Date: Aug 10, 2006

Printed Name and Title: Rodney C. Hoppe, Partner -